Alector to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

Rhea-AI Summary

Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced management participation in a virtual fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on June 10, 2020, at 3:50 p.m. ET. The live webcast can be accessed on Alector's Investors page, with a replay available for 30 days post-event. Alector's approach targets immune dysfunction in neurodegenerative diseases, specifically in frontotemporal dementia and Alzheimer's disease, aiming to repair genetic mutations affecting the brain's immune response.

News Market Reaction – ALEC

-0.82%

-0.82% Session move

In the trading session that priced this news, ALEC declined 0.82%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of management will participate in a virtual fireside chat at the Goldman Sachs 41^st Annual Global Healthcare Conference on Wednesday, June 10, 2020, at 3:50 p.m. ET.

A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 30 days following the event.

About Alector

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Source: Alector, Inc.

Contacts

Media:
1AB
Dan Budwick, 973-271-6085
dan@1abmedia.com
or
Investors:
Alector, Inc.
ir@alector.com

FAQ

When is Alector's fireside chat at the Goldman Sachs Global Healthcare Conference?

Alector's fireside chat is scheduled for June 10, 2020, at 3:50 p.m. ET.

Where can I watch the Alector fireside chat?

The fireside chat can be viewed live on Alector's Investors page, with a replay available for 30 days after the event.

What is Alector's focus in biotechnology?

Alector focuses on immuno-neurology, targeting immune dysfunction as a treatment approach for neurodegenerative diseases.

What diseases does Alector target with its therapies?

Alector targets frontotemporal dementia and Alzheimer's disease with its therapies.

What is the ticker symbol for Alector?

Alector's stock ticker symbol is ALEC.